Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Xcyte raises $29.9mm in IPO

Executive Summary

Xcyte Therapies (immune response enhancing drugs) netted $29.9mm in its initial public offering through the sale of 4.2mm shares priced at $8 per share. The company previously filed for an $86mm initial offering in December of 2000, but later withdrew it due to market conditions; the current IPO was preliminarily priced between $13-15 apiece for 4mm shares.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies